CA Patent

CA3100146A1 — Formulations/compositions comprising ibrutinib

Assigned to Janssen Pharmaceutica NV · Expires 2019-12-19 · 6y expired

What this patent protects

Disclosed are formulations/compositions comprising ibrutinib: (I) as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

USPTO Abstract

Disclosed are formulations/compositions comprising ibrutinib: (I) as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Drugs covered by this patent

Patent Metadata

Patent number
CA3100146A1
Jurisdiction
CA
Classification
—
Expires
2019-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.